Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 13/20 | 1.00 |
| ▸ | SKP2 | Q13309 | 13/20 | 1.00 |
| ▸ | GLO1 | Q04760 | 8/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17506540 | 0.89 | CKS1B (1.00) | CKS1BSKP2GLO1 | |
| SCHEMBL17506541 | 0.88 | CKS1B (1.00) | CKS1BSKP2GLO1 | |
| SCHEMBL17506533 | 0.85 | CKS1B (1.00) | CKS1BSKP2GLO1 | |
| SCHEMBL17506517 | 0.81 | CKS1B (1.00) | CKS1BSKP2GLO1 | |
| SCHEMBL21869671 | 0.78 | CKS1B (0.64) | CKS1BSKP2GLO1 | |
| SCHEMBL17506518 | 0.77 | CKS1B (1.00) | CKS1BSKP2 | |
| SCHEMBL17506543 | 0.75 | CKS1B (1.00) | CKS1BSKP2GLO1 | |
| SCHEMBL17570172 | 0.75 | CKS1B (0.79) | CKS1BSKP2GLO1 | |
| SCHEMBL17506524 | 0.75 | CKS1B (1.00) | CKS1BSKP2GLO1 | |
| SCHEMBL17506527 | 0.74 | CKS1B (1.00) | CKS1BSKP2GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180328-A1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2017-06-21 | — | — | EP | claimed |
| WO-2016025779-A1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-18 | — | — | WO | claimed |
| EP-3180328-B1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| EP-3180328-B1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10040766-B2 | Ubiquitination inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10040766-B2 | Ubiquitination inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10040766-B2 | Ubiquitination inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| EP-3180328-A1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20160068490-A1 | UBIQUITINATION INHIBITORS | MIDCAP FINANCIAL TRUST | 2016-03-10 | — | — | US | disclosed |
| US-20160068490-A1 | UBIQUITINATION INHIBITORS | MIDCAP FINANCIAL TRUST | 2016-03-10 | — | — | US | disclosed |
| US-20160068490-A1 | UBIQUITINATION INHIBITORS | MIDCAP FINANCIAL TRUST | 2016-03-10 | — | — | US | disclosed |
| WO-2016025779-A1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016025779-A1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068490-A1 | UBIQUITINATION INHIBITORS | MDM2, RBX1, NEDD4 | CKS1B 206/4885SKP2 51/4885GLO1 278/4885 |
| US-10040766-B2 | Ubiquitination inhibitors | MDM2, RBX1, NEDD4 | CKS1B 206/4885SKP2 51/4885GLO1 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.